PLT Health Solutions (PLT), in partnership with Laila Nutraceuticals, is launching a botanically-based ingredient called RipFACTOR Muscle Accelerator.
Last year, PLT and Laila conducted clinical trials demonstrating its efficacy at two use levels, ‘performance’ and ‘ultra performance’. With the ultra performance formulation, subjects consuming RipFACTOR reportedly showed as much as a 4x increase in muscle size, a 2x improvement in muscle endurance and a 5x improvement in body strength relative to participants taking a placebo.
Statistically significant improvements in lean body mass, percent body fat and total body fat were also observed. RipFACTOR is available in both a standard and a neutral tasting water-dispersible form, and is suitable for applications from powders to functional foods, shakes, gummies, stick packs and more.
Subjects taking the ‘performance’ dose demonstrated similar strength and endurance benefits to subjects in the placebo group doing twice the amount of exercise
Seth Flowerman, President and CEO of PLT said: “After a 7-year, multi-million-dollar development process involving in-depth screening of hundreds of botanicals, we are proud to deliver a breakthrough ingredient that can significantly and rapidly increase both upper and lower body strength and endurance as well as significantly increase muscle size – all in a low-dosage format. Offering two dosage levels enables formulators to develop targeted SKUs for both emerging and performance athletes,”
A study on the ingredient, done in 2019, focused on resistance training of ‘naive' subjects and examined two different dose levels, a ‘performance’ and ‘ultra-performance’ dose. An innovative ‘efficiency model’ design was employed by including a second placebo group that followed a double exercise regimen.
Subjects taking the ‘performance’ dose demonstrated similar strength and endurance benefits to subjects in the placebo group doing twice the amount of exercise. At the ‘ultra-performance’ dose, the strength and endurance gains were statistically significantly better than subjects completing twice the exercise volume.
Compared to the placebo group, the RipFACTOR group showed a testosterone to cortisol (T:C) ratio that favors anabolism and could be partially responsible for the muscle growth and strength benefits. Manuscripts for the studies done on RipFACTOR will be submitted for publication in 2020.
Barbara Davis, Head of Clinical & Regulatory Sciences for PLT, said: “There really isn't anything else on the market today that drives significant gains in strength as early as two weeks, particularly with a dose less than one gram. RipFACTOR supports improved physical performance and faster results for a broad range of consumers. For formulators, the clinical work provides a broad range of tools to communicate the range of benefits to consumers – with messaging on physiological and performance improvements every step of the way,” she said.
